Followers | 145 |
Posts | 27561 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, April 16, 2020 8:20:06 AM
into is BVXV.
A short description of the company:
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is Phase 3 clinical phase bio pharmaceutical company developing the M-001 Universal Flu Vaccine. M-001 is currently undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. Results of the clinical trial are expected by the end of 2020.
M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 7 completed clinical trials the vaccine was shown to be safe, well tolerated and immunologic to a broad range of flu strains.
More at http://www.biondvax.com/
Disclosure: I own some 270 shares.
Since you are into bios, i think that this one has great
potential. Can you imagine the potential of a universal flu vaccine?
Influenza is not a hot subject nowadays, Corona took all
limelight, but its day will come - hopefully
Recent SLGL News
- Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 01:29:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 01:07:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2024 11:49:02 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 09:05:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 12:10:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2023 01:20:38 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/09/2023 08:41:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 12:15:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/28/2023 12:31:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/27/2023 12:03:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/26/2023 12:48:01 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/10/2023 11:20:35 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 11:10:27 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/27/2023 08:05:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2023 10:20:14 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 07/20/2023 10:00:47 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM